Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:AST
CUSIPN/A
Phone+1-510-4563805
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-403.38%
Return on Equity-79.80%
Return on Assets-59.45%
Miscellaneous
EmployeesN/A
Outstanding Shares55,010,000
Market Cap$102.89
Asterias Biotherapeutics (NYSEAMERICAN:AST) Frequently Asked Questions
What is Asterias Biotherapeutics' stock symbol?
Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AST."
How were Asterias Biotherapeutics' earnings last quarter?
Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) released its quarterly earnings results on Wednesday, May, 9th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.12) by $0.03. The biotechnology company had revenue of $0.48 million for the quarter. Asterias Biotherapeutics had a negative return on equity of 79.80% and a negative net margin of 403.38%. View Asterias Biotherapeutics' Earnings History.
When is Asterias Biotherapeutics' next earnings date?
What price target have analysts set for AST?
2 analysts have issued 12-month price objectives for Asterias Biotherapeutics' shares. Their forecasts range from $6.00 to $11.00. On average, they expect Asterias Biotherapeutics' share price to reach $8.50 in the next year. This suggests a possible upside of 372.2% from the stock's current price. View Analyst Ratings for Asterias Biotherapeutics.
What is the consensus analysts' recommendation for Asterias Biotherapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Asterias Biotherapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Asterias Biotherapeutics stock?
Here are some recent quotes from research analysts about Asterias Biotherapeutics stock:
- 1. According to Zacks Investment Research, "Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company's technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. " (7/10/2018)
- 2. HC Wainwright analysts commented, "We reiterate our Buy rating and 12-month price target of $11 on AST." (6/19/2018)
Are investors shorting Asterias Biotherapeutics?
Asterias Biotherapeutics saw a decrease in short interest in the month of June. As of June 29th, there was short interest totalling 3,136,066 shares, a decrease of 22.5% from the June 15th total of 4,048,193 shares. Based on an average daily trading volume, of 398,001 shares, the short-interest ratio is presently 7.9 days. Approximately 9.6% of the company's shares are short sold. View Asterias Biotherapeutics' Current Options Chain.
Who are some of Asterias Biotherapeutics' key competitors?
Some companies that are related to Asterias Biotherapeutics include MediGene (MDG1), Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Protalix Biotherapeutics (PLX), Neptune Technologies & Bioressources (NEPT), Monash IVF Group (MVF), ABcann Global (ABCN), Horizon Discovery Group (HZD), IMV (IMV), Faron Pharmaceuticals Oy (FARN), Bionomics (BNO), Fennec Pharmaceuticals (FRX) and ImmunoVaccine (IMMVF).
Who are Asterias Biotherapeutics' key executives?
Asterias Biotherapeutics' management team includes the folowing people:
- Mr. Michael H. Mulroy, Chief Exec. Officer, Pres & Director (Age 52)
- Dr. Edward D. Wirth III, M.D., Ph.D., Chief Medical Officer (Age 53)
- Dr. Katharine E. Spink, Consultant (Age 44)
- Mr. Stephen L. Cartt, Advisor & Director (Age 55)
- Mr. Ryan D. Chavez, CFO & Gen. Counsel (Age 42)
Has Asterias Biotherapeutics been receiving favorable news coverage?
Press coverage about AST stock has been trending somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Asterias Biotherapeutics earned a news sentiment score of 0.05 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 44.47 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Asterias Biotherapeutics?
Shares of AST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Asterias Biotherapeutics' stock price today?
One share of AST stock can currently be purchased for approximately $1.80.
How big of a company is Asterias Biotherapeutics?
Asterias Biotherapeutics has a market capitalization of $102.89 million.
How can I contact Asterias Biotherapeutics?
Asterias Biotherapeutics' mailing address is 6300 Dumbarton Cir, FREMONT, CA 94555-3644, United States. The biotechnology company can be reached via phone at +1-510-4563805.
MarketBeat Community Rating for Asterias Biotherapeutics (NYSEAMERICAN AST)
MarketBeat's community ratings are surveys of what our community members think about Asterias Biotherapeutics and other stocks. Vote "Outperform" if you believe AST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AST will underperform the S&P 500 over the long term. You may vote once every thirty days.
